Exchange: NASDAQ·Updated 04:29 AM EDT
DNTH logo

DNTH Dianthus Therapeutics Inc

$110.76
$0.00
(0.00%)
Pre-Market
Prev Close $110.76
Reported EarningsAug 4
Mkt Cap$6.27B
Vol1,168.00

About DNTH

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
56

Bullish Sentiment

How do you feel about DNTH?

Advertisement|Remove ads.